These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11595827)

  • 1. Association of insulin resistance with hyperandrogenia in women.
    Pugeat M; Ducluzeau PH; Mallion-Donadieu M
    Horm Res; 2000; 54(5-6):322-6. PubMed ID: 11595827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome.
    Holte J
    Baillieres Clin Endocrinol Metab; 1996 Apr; 10(2):221-47. PubMed ID: 8773746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress.
    Barbieri RL
    J Reprod Med; 1994 May; 39(5):327-36. PubMed ID: 8064699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the PCOS phenotype with age.
    Hsu MI
    Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus.
    García-Romero G; Escobar-Morreale HF
    Curr Diabetes Rev; 2006 Feb; 2(1):39-49. PubMed ID: 18220616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women.
    Falcone T; Finegood DT; Fantus IG; Morris D
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1653-7. PubMed ID: 2146285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
    Hernández-Jiménez JL; Barrera D; Espinoza-Simón E; González J; Ortíz-Hernández R; Escobar L; Echeverría O; Torres-Ramírez N
    Gynecol Endocrinol; 2022 Jan; 38(1):2-9. PubMed ID: 34787028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia.
    Rosenfield RL
    J Am Acad Dermatol; 2001 Sep; 45(3 Suppl):S95-104. PubMed ID: 11511859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome.
    Sozen I; Arici A
    Obstet Gynecol Surv; 2000 May; 55(5):321-8. PubMed ID: 10804539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China.
    Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W
    J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
    Xita N; Tsatsoulis A
    J Clin Endocrinol Metab; 2006 May; 91(5):1660-6. PubMed ID: 16522691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism.
    Luque-Ramírez M; Alpañés M; Escobar-Morreale HF
    Fertil Steril; 2010 Nov; 94(6):2214-21. PubMed ID: 20097337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
    Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
    Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.